UnitedHealth Group (UNH) is facing deep structural problems and significant regulatory headwinds that could worsen over the next 12-18 months. Due to "appalling" accounting transparency and fundamental business issues, the analyst's bull case scenario suggests a potential downside to $257 per share. The core thesis is that UNH is in the "too hard pile" and its past growth may have been inflated. For investors seeking exposure to the managed care sector, competitors Humana (HUM) and CVS Health (CVS) are presented as "cleaner stories" with more manageable risks. Investors should be cautious of following Berkshire Hathaway's small and potentially ill-timed investment into UNH.

UnitedHealth Group (UNH)

• The stock is described as being "under assault," having fallen significantly from a high of around $600 to below $300 at the time of the podcast. The analyst from Baird, Michael Ha, has an underperform rating on the stock.

• The company's main growth driver, Optum Health, is experiencing "fundamental cracks" and "real business problems." This division, once considered the "crown jewel," was built to own primary care clinics and manage patient care to lower costs and capture higher margins than the traditional insurance business.

• The core problem stems from a U.S. government policy change called the V28 risk model revision. This new model makes it much more difficult for providers to get paid more for sicker patients by tightening the rules around "risk coding."

• The podcast argues that UNH was a particularly "aggressive coder" under the old system. An analysis of the Los Angeles market showed that after UNH acquired a physician group in 2019, the risk scores for its patients increased dramatically from 1.01 to 1.5, suggesting they were maximizing revenue under the old rules.

• Because UNH was so aggressive, the V28 change has a much larger negative impact on it than on its competitors. The financial headwind is estimated to be $11 billion over three years, which represents a nearly 20% negative rate impact on the Optum Health business.

• As a result, Optum Health's long-term operating profit margin target was cut from 8-10% down to 6-8%. The value-based care clinics, the core of the strategy, are currently operating at just 1% margins.

• Serious concerns were raised about the company's lack of transparency and accounting practices, which were compared to the old, opaque version of General Electric (GE):

  • Poor Disclosure: The company's earnings releases are described as "appalling" and too brief for a company of its size, making it nearly impossible for analysts to truly model the business.
  • Gains on Sale: UNH was including gains from selling parts of its business in its operating earnings without clearly disclosing it. This amounted to over $3 per share in earnings, which masked the poor performance of the underlying business.
  • Intercompany Transactions: An inside source suggested that Optum was charging the UNH insurance arm up to 2x the rates it charged external customers. This could have been a way to make the high-growth Optum division appear more profitable than it really was by simply moving money from one part of the company to another.

Takeaways

• The analyst's core thesis is that UNH is facing deep, structural problems, not just a temporary downturn. The belief is that "things could get worse before it can get better" over the next 12-18 months.

• The company's past growth and profitability may have been inflated by aggressive coding and accounting maneuvers that are now being unwound by regulatory changes and increased scrutiny.

• Due to the extreme complexity and "appalling" lack of disclosure, the stock is considered to be in the "too hard pile." It is very difficult for investors to assess the true health and future earnings power of the company.

• The risk/reward profile appears unfavorable. The analyst's bull case scenario puts the stock at $257, which represents 15% downside from the $305 price mentioned in the podcast.

• For investors considering buying the dip, the advice is to have a "multi-multi-year duration" and be prepared for significant execution risk and a potentially long and difficult turnaround.

Humana (HUM) & CVS Health (CVS)

• These companies are competitors to UNH and also operate in the value-based care space (Humana's Centerwell and CVS's Oak Street Health).

• However, a key difference is that these value-based care businesses represent a much smaller portion of their overall earnings. For example, Oak Street is only about 2% of CVS's enterprise earnings.

• Because their exposure is smaller, the negative financial impact from the V28 risk model revision is much more manageable for them compared to the large, structural impact on UNH.

• Humana was specifically highlighted for doing a "terrific job" at offsetting the headwinds from the V28 changes.

Takeaways

• The analyst describes these competitors as "cleaner stories" within the managed care sector.

• Investors who are interested in the healthcare sector but are concerned about the company-specific accounting and structural issues at UNH might find its peers to be less risky alternatives.

Berkshire Hathaway (BRK.A / BRK.B)

• It was noted that Warren Buffett's Berkshire Hathaway recently purchased a position in UnitedHealth (UNH), which some investors might see as a bullish signal.

• However, the podcast provides important context to temper that view:

  • The position is "quite small" relative to Berkshire's overall portfolio.
  • The purchase was made before UNH reported its very negative second-quarter earnings and withdrew its financial guidance, meaning Berkshire may not have had the full picture at the time of its investment.
  • The analyst notes the irony that UNH, with its opaque financials, is the type of company that would normally be in the "too hard pile" that Berkshire's leadership has historically avoided.

Takeaways

• Investors should be cautious about following Berkshire into this stock based on the news of their purchase alone.

• The timing and small size of the investment suggest it may not be a high-conviction bet made with all the negative information that has since come to light.